Zentalis Pharmaceuticals
ZNTL
120 hedge funds and large institutions have $1.24B invested in Zentalis Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 36 closing their positions.
3,086% more call options, than puts
Call options by funds: $17.1M | Put options by funds: $536K
33% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 33
1.84% more ownership
Funds ownership: 113.58% → 115.41% (+1.8%)
12% less funds holding
Funds holding: 137 → 120 (-17)
23% less capital invested
Capital invested by funds: $1.61B → $1.24B (-$371M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
44% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$54.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$25M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$22.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.3M |
| 5 |
Morgan Stanley
New York
|
+$9.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$42.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$27M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$24.3M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$17M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$14M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$3K | -137 | Closed |
|
|
BWL
152
Bogart Wealth LLC
Mclean,
Virginia
| – | -$2.51K | -125 | Closed |
|
|
RTL
153
Red Tortoise LLC
Atlanta,
Georgia
| – | -$1.67K | -83 | Closed |
|
|
BIA
154
Bell Investment Advisors
Oakland,
California
| – | -$1.52K | -76 | Closed |
|
|
AF
155
Allworth Financial
Folsom,
California
| – | -$141 | -7 | Closed |
|
|
C
156
Covestor
London,
United Kingdom
| – | -$15 | -1 | -20% |
|
ZNTL Hedge Fund Activity: Q4 2023 in Review
120 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2023, worth a combined $1.24B — down 23% from $1.61B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ZNTL and 20 opened new positions — a net loss of 16 holders — while 33 trimmed existing stakes and 44 added.
The largest buyer was Eventide Asset Management, adding an estimated $54.7M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $42.1M sold.
- 120 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2023, down from 137 in Q3 2023.
- Funds reported $1.24B of Zentalis Pharmaceuticals stock for Q4 2023, down 23% quarter-over-quarter.
- 20 funds opened new Zentalis Pharmaceuticals positions in Q4 2023 and 36 closed out, a net change of -16 holders.
- The largest Zentalis Pharmaceuticals buyer in Q4 2023 was Eventide Asset Management, an estimated $54.7M added.
- The largest Zentalis Pharmaceuticals seller in Q4 2023 was Avidity Partners Management, an estimated $42.1M sold.
Based on aggregated 13F filings for Q4 2023.